Peter MacCallum Cancer Centre welcomes the Therapeutic Goods Administration (TGA) announcement that Novartis Kymriah® (tisagenlecleucel, formerly CTL019) has been approved for treating two aggressive blood cancers.
The Peter MacCallum Cancer Centre acknowledges the traditional
owners of the land on which our five sites are located throughout Victoria.
We recognise their strength and resilience and pay our respects
to their Elders past and present.